Phase 3 N=70 Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
Hypertension · Diabetes
Primary: Change in Central Systolic Blood Pressure (SBP) — 125.3; 127.8; 121.6; 123.8 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=844 Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline — 33.1; 5.3 percentage of…
Phase 3 N=413 Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.
Plaque Psoriasis
Primary: Percentage of Participants Who Achieved at Least a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline — 28.8; 5.8…
Phase 3 N=584 ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Gastric Cancer
Primary: Overall Survival (OS) - Percentage of Participants With an Event — 62.8; 56.8 percentage of participants
Phase 3 N=87 Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Ocular Itching Score Compared to Placebo Period1 — 0.4; 1.7 score — p=<0.001
Phase 3 N=17 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
Raynaud · Scleroderma
Primary: The Time to Recover 50% of Fall in the Baseline Skin Temperature. — 7.5; 8.2; 7.9 minutes
Phase 3 N=40 Atripla to Raltegravir Switch Study for CNS Toxicity
HIV Infection
Primary: The Rate of Neuropsychiatric and Central Nervous System (CNS) Toxicity of Raltegravir Therapy After 4 Weeks on Treatment — 26 percentage improvement in CNS score
Phase 3 N=545 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
Glioblastoma
Primary: Overall Survival (OS) Time — 26.3; 26.3 Months — p=0.8623
Phase 3 N=30 A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
Restless Legs Syndrome · End-Stage Renal Disease
Primary: Ratio From Baseline to the End of the 2-week Maintenance Period in Periodic Limb Movement Index (PLMI) — 1.16; 0.51 ratio — p=0.0232
Phase 3 N=10 Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
Chronic Hepatitis C
Primary: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) — 50.0 percentage of subjects achieving SVR
Phase 3 N=108 Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
Chronic Hepatitis C
Primary: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) — 88.0 percentage of subjects achieving SVR
Phase 3 N=2,055 Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
Influenza · Fever
Primary: Number Of Subjects Reporting Solicited Local and Systemic Adverse Events and Other Indicators Of Reactogenicity After Any Vaccination. — 422; 202; 370; 160 Subjects
Phase 3 N=346 Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
Tumor Lysis Syndrome
Primary: Serum Uric Acid (sUA) Level Control — 514.0; 708.0 mg x hour/dL — p=<0.0001
Phase 3 N=13 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
Prevention of the Meningococcal Disease
Primary: Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule — 1.18; 53; 2.27; 143 Titers
Phase 3 N=106 Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Cockcroft-Gault (CG) Equation at Week 24 (Cohort 1) — 72.9; -5.2 mL/min